Ishares Msci Spain ETF vs 10X Genomics Inc — how do they compare? Ishares Msci Spain ETF trades at $57.83 (market cap $2.30B), while 10X Genomics Inc trades at $79.19 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 4.4× Ishares Msci Spain ETF's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Ishares Msci Spain ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Spain ETF for 40 Days and 10X Genomics Inc for 92 Days on average.
| EWP | TXG | |
|---|---|---|
Market Cap | $2.30B | $10.07B |
Volume | 845,747 | 5,657,286 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.23 | $97.74 |
52-Week Low | $48.33 | $11.48 |
Typical Hold Time | 40 Days | 92 Days |
Enterprise Value | — | $9.59B |
Signals from Pluang's Aura AI — not financial advice
EWP, the iShares MSCI Spain ETF, trades at $57.82, down 1.73% on the day amid a bearish technical signal. The ETF offers concentrated exposure to Spanish equities with a discounted 16x P/E and 2.7% yield, heavily weighted in financials and utilities. Recent ECB rate hikes to 2.5% and energy-driven inflation pressures create macroeconomic headwinds for European markets.
While EWP provides attractive valuation and yield, the bearish technical outlook and ECB tightening cycle present near-term challenges. The concentrated portfolio in Spanish banks and utilities offers stability but limits diversification. Upside potential depends on Spain's economic resilience amid broader eurozone pressures.
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.
Read more on EWP →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →